Presbyopia in Breast Cancer Survivors

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT00271661
First received: December 30, 2005
Last updated: December 8, 2011
Last verified: December 2011
  Purpose

Chemotherapy drugs, used in cancer treatments, may change the timing of a vision condition known as presbyopia. Presbyopia is the inability to focus the eye on close objects, by a process called accommodation. It is caused by an increase in the stiffness of the lens of the eye that occurs naturally with aging. Currently, there are no known treatments that can be used to prevent or delay presbyopia. As a result, the risk, in later life, of having this condition is essentially 100%.

The purpose of this research is to determine whether chemotherapy drugs are delaying the age at which people develop symptoms of presbyopia. We hope to establish that presbyopia can in fact be delayed with the use of drugs, which would ultimately lead to further research in this area.


Condition
Presbyopia

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Presbyopia in Breast Cancer Survivors

Resource links provided by NLM:


Further study details as provided by AHS Cancer Control Alberta:

Enrollment: 0
Study Start Date: August 2005
Estimated Study Completion Date: May 2006
Detailed Description:

Chemotherapy drugs, used in cancer treatments, may change the timing of a vision condition known as presbyopia. Presbyopia is the inability to focus the eye on close objects, by a process called accommodation. It is caused by an increase in the stiffness of the lens of the eye that occurs naturally with aging. Currently, there are no known treatments that can be used to prevent or delay presbyopia. As a result, the risk, in later life, of having this condition is essentially 100%.

The purpose of this research is to determine whether chemotherapy drugs are delaying the age at which people develop symptoms of presbyopia. We hope to establish that presbyopia can in fact be delayed with the use of drugs, which would ultimately lead to further research in this area.

  Eligibility

Ages Eligible for Study:   45 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

primary care clinic

Criteria

Inclusion Criteria:

  • ages 45-60
  • ability to understand and provide written consent in English

Exclusion Criteria:

  • blindness
  • visual defects leading to accommodative failure
  • severe myopia
  • recurrent breast cancer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00271661

Sponsors and Collaborators
AHS Cancer Control Alberta
Investigators
Principal Investigator: John Mackey, Dr. AHS Cancer Control Alberta
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00271661     History of Changes
Other Study ID Numbers: BR-1-0072, ETHICS 22007
Study First Received: December 30, 2005
Last Updated: December 8, 2011
Health Authority: Canada: Health Canada

Keywords provided by AHS Cancer Control Alberta:
presbyopia; breast cancer survivors

Additional relevant MeSH terms:
Breast Neoplasms
Presbyopia
Breast Diseases
Eye Diseases
Neoplasms
Neoplasms by Site
Refractive Errors
Skin Diseases

ClinicalTrials.gov processed this record on October 23, 2014